Monogenic Diabetes due to ABCC8/KCNJ11 Mutation: Case Study and Review of Literature by Karunakaran, V et al.
Karunakaran V, Wei C and Bano G
 
| Volume 1; Issue 1 (2020) | Mapsci-JEMR-1(6)-006| Review Article 
Citation: Karunakaran V, Wei C and Bano G. Monogenic Diabetes due to ABCC8/KCNJ11 Mutation: Case Study 
and Review of Literature. J Endo Metabol Res. 2020;1(6):1-16. 
 
 
Journal of Endocrinology and Metabolism Research 
Karunakaran V, et al., 2020- J Endo Metabol Res 
Review Article 
 
 
Monogenic Diabetes due to 
ABCC8/KCNJ11 Mutation: Case Study and 
Review of Literature 
Karunakaran V
1
, Wei C
2
, and Bano G
1
   
Abstract 
Monogenic diabetes arises due to mutation in a single-gene and is 
recognized by their striking familial inheritance pattern. This form of 
diabetes is inherited in an autosomal dominant or recessive fashion, 
unlike polygenic Type 1 (autoimmune) or type 2 diabetes caused by the 
combined action of more than one gene [1-11]. Monogenic diabetes is 
classified into three main groups: Neonatal diabetes mostly presents in 
the first six months of birth, maturity onset diabetes of the young 
(MODY) and maternally inherited mitochondrial diabetes. 
These mutations run in the family and have a predictable course. Most 
of the monogenic diabetes is treated with oral medications like 
sulfonylurea rather than insulin. ABCC8/KCNJ11 gene mutations also 
cause monogenic diabetes. This gene mutation has been found in ~50% of congenital hyperinsulinemia 
(CHI) patients. In such cases diabetes commonly presents in the neonatal period (transient or 
permanent) or at adolescence / early adulthood [1].  
We present a 58-year-old diabetic lady, who was detected with ABCC8 mutation during the cascade 
testing [8]. She was diagnosed with diabetes at the age of 12 [8]. Her son had history of neonatal 
hypoglycaemia and developed diabetes at the age of 15. He was the index case who was found to have 
ABCC8 mutation. The family has several other members diagnosed with diabetes. The aim of the article 
is to increase awareness and understanding of monogenic diabetes among the medical practitioners in 
adult population with diabetes so that the genetic testing can be offered in a cost effective manner. 
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Introduction  
The physiological regulation of insulin 
release from the pancreatic beta-cells is 
now fairly well understood. Understanding 
the molecular basics of Insulin secretion 
from the pancreatic beta-cell in response to 
the rise in plasma glucose has paved the 
way for identifying a variety of mutations 
causing monogenic diabetes. In β- cells, 
the main stimulus for insulin release is 
elevated blood glucose levels following a 
meal. Under physiological circumstances, 
the postprandial plasma glucose enters the 
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pancreatic beta-cell through GLUT2 
(SLC2A2), transporter, which is located on 
the beta-cell surface. Glucose is then 
phosphorylated by Glucokinase enzyme to 
glucose-6-phosphate, and this enters the 
Krebs cycle, causing increased ATP 
production. The change in ATP: ADP ratio 
causes the closure of Potassium sensitive 
Adenosine-Tri- Phosphate (KATP) 
channels, resulting in membrane 
depolarization and opening of the Voltage-
gated Calcium channels with a resultant 
influx of extracellular Calcium ion into the 
pancreatic beta-cell. This influx leads to 
degranulation of insulin-containing 
vesicles and Insulin release. Figure 1 
explains the physiology of Insulin release 
from a pancreatic beta-cell and the 
common mutations involved in causing 
monogenic diabetes [2]. 
Currently, there are at least 41 identified 
genes involved in monogenic diabetes 
(Table 1) [1]. The commonest 4 causes of 
MODY are MODY2 (GCK) and MODY3 
(HNFIA), MODY1 (HNF4A) and MODY5 
(HNF1B). MODY2 and MODY 3 account for 
30%-60% of all MODY, whereas, MODY 1 
and MODY 5 together account for 10% of 
all MODY. Pathogenic variation in 10 other 
genes can result in 20% of all MODY [1]. A 
substantial number of MODY may be 
caused by variation in un-identified genes 
or could not be identified by the old 
genetic testing methods [3]. 
ABCC8 (ATP-binding cassette transporter, 
sub-family C, member 8) and KCNJ11 
(Potassium inwardly rectifying channel, 
subfamily J, member 11) gene mutations 
constitute 40% of neonatal diabetes. They 
result in either gain of function or loss of 
function mutation of the KATP channel, 
but evidence indicates that the majority are 
due to gain of function mutation. With a 
gain of function mutation, the KATP 
channel remains open, and there is no 
insulin release resulting in diabetes Figure 
2. With the loss of function mutation, the 
KATP channel is not manufactured, or it is 
formed, but trapped in the endoplasmic 
reticulum Figure 3, or it traffics to the cell 
surface but is unresponsive to mgADP thus 
resulting in its closure and dysregulated 
insulin release Figure 4. This causes 
congenital hyperinsulinemia and the 
resultant hypoglycemia during the 
neonatal period [4, 5]. In pancreatic b cells 
glucose release requires Ca+ influx Low 
blood glucose: Decrease ATP-Increase K+ 
efflux-increase Increase depolarization-
decrease Ca2+influx and decrease insulin 
secretion 
Elevated blood glucose: Increase ATP-
decrease K+ efflux, decrease Depolarization, 
increase Ca2+ influx and increase insulin 
secretion.  
Prevents trafficking KATP channel 
Membrane stays in depolarized state 
regardless of metabolic state Results in 
dysregulated insulin secretion.  The next-
generation sequencing technology analyses 
the pathogenic variants, increasing the 
chances of detection of several novel 
pathological Variants of Unknown 
Significance (VUS). This technology also 
raises ethical and clinical dilemmas that 
deserve a careful and conscientious 
interpretation, often with a 
multidisciplinary (MDT) approach with 
multi-center collaboration [1, 6]. 
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Table 1: Maturity-Onset Diabetes of the Young (MODY):  Associate Genes and Clinical Features 
Gene 
%age of 
diabetes 
Clinical Features 
Microvascular 
complications 
HNF4A (MODY1) 5-10% 
Birth weight is usually more than 800gm 
Common Neonates may  develop transient 
hyperinsulinemichypoglycemia  Defect in 
insulin secretion tends to be progressive 
GCK (MODY2) 30-50% 
Mild fasting hyperglycemia at birth 
Mostly asymptomatic Rare 
Often incidental diagnosis 
HNF1A (MODY3) 30-65% 
Some cases present with transient 
neonatal hyperinsulinemichypoglycemia 
Insulin secretory defect is progressive 
Common 
Renal glycosuria is present 
Oral glucose tolerance test (OGTT) is 
required to establish early diagnosis 
PDX1 1 (MODY4) 1% Overweight or obesity in some cases Not known 
HNF1B (MODY5) 5% 
Intrauterine growth retardation (IUGR) 
Common Renal and urogenital tract 
anomalies  Hypoplastic Pancreas 
NEUROD1 
(MODY6) 
1% Some case may be overweight or obese Not known 
KLF11 (MODY7) 
Less than 
1%  
Not known 
CEL (MODY8) 
Less than 
1% 
Atrophy of Pancreas 
Rare Pancreatic exocrine insufficiency 
Lipomatosis and Fibrosis 
PAX4 (MODY9) 
Less than 
1%  
Not known 
INS1 (MODY10) 
Less than 
1%  
Not known 
BLK (MODY11) 
Less than 
1% 
  
Some case may be overweight or obese Not known 
  
ABCC8 (MODY12) 
Less than 
1% 
Same as HNF1A and HNF4A Not known 
 Less than 
1% 
Same as HNF1A and HNF4A Not known KCNJ112 
(MODY13) 
APPL1 ( MODY14) 
Less than 
1% 
Some case may be overweight or obese 
 
Not known 
  
 
Figure 1: Pancreatic b-cell glucose detection and Insulin release in a normal cell. 
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Figure 2: Gain of function (activating) mutation in ABCC8 or KCNJ11 (KATP channel). 
 
KATP channel remains open with efflux of K
+
 No membrane depolarization. No influx of 
calcium and no insulin secretion. 
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Figure 3: Loss of function mutation in ABCC8 or KCNJ11 9(KATP channel) results inreduction 
or absence of protein at the membrane. 
 
Figure 4: Loss of function mutation in ABCC8 or KCNJ11 (KATP) with reduced responsiveness of KATP 
to mgADP. 
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Despite our current understanding, it is 
also likely that the KATP channel-
independent mechanisms of β-cell insulin 
release also exist, and the ongoing research 
will help to understand this further. This 
may explain the variable penetrance and 
presentation of diabetes within the same 
family that ranges from neonatal 
hypo/hyperglycemia, remission of neonatal 
hyperglycemia with relapse in early 
adulthood, the first presentation in 
adulthood, or only as gestational diabetes 
or glucose intolerance. The potential for 
misdiagnosing monogenic diabetes as 
either late onset Type 1 or early Type 2 still 
exists, and could result in mismanagement. 
These patients often do not achieve 
optimal glycemic control with therapies 
used for common forms of diabetes and are 
prone to serious risks of hypoglycemia. 
Without the right diagnosis, they may also 
never achieve a good quality of life. 
ABCC8/KCNJ [11] mutations are easy to 
treat with sulfonylurea, or may not require 
medical therapy in some cases depending 
on the type of pathogenic variant. If 
identified early with a detailed history, 
particularly family history and cascade 
genetic testing, these patients can have 
appropriate follow up with prompt 
intervention and treatment when clinically 
indicated. 
Case Report 
A 58-year-old lady was referred for 
management of her diabetes by the 
Genetics department to the inherited 
diabetes clinic after a Heterozygous novel 
missense mutation was detected in the 
ABCC8 gene during cascade screening. She 
was diagnosed as Type 2 diabetes 
incidentally from a routine screening at 
school when she was 12 years of age. She 
was managed with diet alone for several 
years following the diagnosis. She was 
treated with insulin for optimization of 
glycemic control during preconception 
between 2002 and 2003. Insulin was 
discontinued, and Gliclazide was 
prescribed after 2003. However, she 
experienced several episodes of 
hypoglycemia, in particular, post-exercise, 
and eventually, Gliclazide was 
discontinued in 2013. Her past medical 
history includes appendicectomy, vitamin 
deficiency, and hyperlipidemia. Her 
current medication is only Vitamin D and 
Atorvastatin. She does not smoke, drinks 12 
units of alcohol/week, and leads an active 
lifestyle, which includes regular swimming 
and cycling sessions. Several members of 
her family have developed diabetes in their 
twenties spanning over four generations, as 
depicted in the pedigree chart Figure: 5. 
Figure 5: Pedigree Tree. 
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Clinical examination revealed a short-
statured female with a height of 149. 5cm, a 
body weight of 46kg with a BMI of 20.5. 
Her HBA1C has ranged between 42 to 
51mmol/mol. Her Total cholesterol was 
5.4mmol/L, Triglycerides 0.67mmol/L, 
HDL cholesterol 3.21mmol/L and 
Cholesterol/HDL ratio- 1.7. Her other 
investigations, including urine albumin 
creatinine ratio (ACR), renal ultrasound, 
and the annual diabetic eye screening, 
were unremarkable [10]. She has no 
diabetes-related micro or macrovascular 
complications. She has a good diabetes 
control with diet and exercise alone. 
Mutation Result 
Result Heterozygous Mutation Identified 
 Gene: ABCC8 
 Location: Exon 37 
Mutation 
details 
DNA Description:  c.4522G  A 
 
Protein description: p.Ala1508Thr 
(p.A1508T) 
 
Consequence: Missense 
 
Her son was the first in the family to be 
diagnosed with this pathogenic variant in 
the ABCC8 gene at the age of 16 years. He 
is currently 23 years old. He was born 
prematurely at 34 weeks with a low APGAR 
score. 
His birth weight was 2.7kg (large for age), 
he had recurrent neonatal hypoglycemia 
and cerebral palsy. His hypoglycemia at 
birth was managed with frequent feeds and 
Diazoxide. Hypoglycemic episodes were 
transient, and he was in remission until 15 
years of age. He then presented with 
hyperglycemia. Due to the significance of 
his neonatal history, genetic testing was 
undertaken, and further cascade screening 
has been undertaken in his first degree 
relatives. 
 
Discussion 
Potassium ATP Channel 
The potassium sensitive ATP channel is a 
hetero-octamertrans membrane channel. It 
has four SUR1- sulfonylurea receptors that 
regulate four, pore-forming Kir 6.2 
(inward-rectifier potassium ion channels) 
Figure 6. They were first identified in 
cardiac muscle in the 1980s and were 
subsequently found to be present in 
skeletal muscle, smooth muscle, pancreatic 
beta cells, and neurons. Sulfonylurea 
components of the channel were 
discovered a decade later, and it was 
realized that the co-expression of SUR1 
receptor proteins is essential in sensitizing 
the pore-forming potassium channel to 
nucleotides like ATP/ADP and 
sulfonylureas [10]. On binding with ATP, 
the channel closes, causing membrane 
depolarization and opening of voltage-
gated calcium channels, this  results in 
extracellular calcium ions influx into the, 
which eventually causes exocytosis of 
insulin and normalization of blood glucose 
levels 7 (Figure.1). 
Figure 6: The structure of the KATP 
channel. 
 
The KATP channel is a hetero- octamer 
composed of Sulfonylurea recetor (SUR) 
and 4 Kir6 subunits [3] are centrally 
located and form the pore and SUR are 
peripherally 
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The gating mechanisms that are involved 
in the opening and closing of KATP 
channels can be ligand dependant or 
independent. The ligand-independent 
mechanisms are not clearly understood 
and are thought to be a result of the 
recruitment of protein kinases A and C, 
changes in membrane potential, or a state 
of selectivity filter5 that allows potassium 
transport despite metabolic activity within 
the cell. 
On the other hand, ligand dependant 
mechanisms involve PIP2 
(phosphatidylinositol 4, 5 bisphosphates) 
and Nucleotides. The binding of PIP2 and 
presence of Magnesium ions (causing 
conversion of MgATP to MgADP) activates 
and opens the gate, whereas the binding of 
ATP (in the absence of Mg2+ ions) causes 
channel closure Figure 7 and Figure 8. 
There are four Kir subunits, but the 
binding of even one subunit with ATP is 
enough to cause the closure [25]. This 
mechanism is not clearly understood and it 
could be that the ATP binding to all four 
subunits acts in a concerted way or 
independent of each other [8, 9]. 
There are three forms of the sulfonylurea 
receptor, SUR1 encoded by the ABCC8 
gene, and SUR2A and SUR2B, which are 
splice variants arising from a single ABCC9 
gene.
Figure 7:  With the closed ATP channel the interaction between 1 Kir6 and 1 SUR subunit. 
 
SUR has 3 transmembrane Domains 
(TMDs), TMD0, TMD1 and TMD2 and 2 
Nucleotide binding Domains (NBDs) NBD1 
and NBD2. The interaction between SUR 
and Kir takes place via TMD0 and a linker 
region called L0 localised between TMDs. 
ATP is bound to NBD1 and NBD2 when 
KATP channel is closed so no efflux of K. 
ATP inhibits Kir subunit and stops opening 
of KATP channel 
Upon hydrolysis of ATP and formation of 
ADP, NBD2 binds to mgADP 
The binding is signalled to Kir through the 
TMD0 and L0 region of SUR 
This stops the inhibitory effect of ATP on 
the Kir and results in opening of K channel 
with influx of calcium and release of 
insulin. 
ABCC8 and KCNJ11 gene
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ABCC8 gene belongs to the ABC group of 
genes which encodes ATP binding cassette 
transporters. KATP is one such transporter. 
It encodes the SUR1 protein part of the 
Potassium channel [10]. A BCC8 gene is 
located on chromosome 11p15.1 and has 39 
exons translating into 1581 or 1582 amino 
acid protein. KCNJ11 gene also has the same 
chromosomal location as ABCC8 but only 
has one exon and translates into a 390 
amino acid protein (Kir 6.2 Protein).
 
Figure 8: With ATP channel open the interaction between 1 Kir6 and 1 SUR subunit. 
 
Both Autosomal dominant and recessive 
mutations in the ABCC8/KCNJ11 gene 
could result in either loss or gain of 
function. However, the majority of the loss 
of function mutation is due to recessive 
mutations in the ABCC8/KCNJ11 gene. This 
causes either a faulty KATP channel that 
does not migrate to the cell membrane or 
KATP channel that incorporates into the 
cell membrane but is less responsive to 
MgADP stabilization of the channel [10] 
This results in no potassium efflux across 
cell membrane, and the continued 
depolarization of the membrane, that leads 
to dysregulated and persistent Insulin 
release and hypoglycemia in the neonatal 
period. A few dominant missense 
mutations have been described, which 
results in KATP channels that traffic to the 
cell surface normally but are less sensitive 
to Mg+ADP Figure 3 and Figure 4. These 
are responsive to Diazoxide therapy. Some 
dominant mutations have also been 
reported with faulty manufacture of the 
KATP channel that does not reach the cell 
membrane and hence remains resistant to 
medical therapy [9]. 
A gain of function mutation results in the 
KATP channel that is less responsive to 
ATP with the resultant KATP channel that 
is continuously open Figure 2. These 
patients may present with transient or 
permanent neonatal diabetes or onset of 
diabetes later in life [2]. This variable 
penetrance is still not clearly understood, 
and could also be related to KATP 
independent mechanisms of Insulin release 
from the β-cell, which is not yet identified. 
Both dominant and recessive ABCC8 
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mutations and most dominant mutations 
of KCNJ11 gene have been associated with 
the gain of function [10]. 
Both our patient and her son have a novel 
pathogenic variant that has not been 
described before. 
As in our index case, the biphasic 
presentation of neonatal 
hypo/hyperglycemia, remission in early 
childhood followed by diabetes later in life 
has been described in ABCC8/KCNJ11 
mutations. This is associated with 
dominant mutations, and the underlying 
mechanisms for this are not understood. 
Laboratory study of mouse models with 
dominant homozygous loss of function 
mutation showed a similar biphasic picture 
of hyperinsulinemichypoglycemia followed 
by diabetes later. 
This was related to a decrease in Insulin 
content despite normal β-cell volume. 
However, a heterozygous mutation in mice 
did not result in a disease [11]. 
Clinical Manifestations 
ABCC8/KCNJ11 mutations could present 
with any or combination of the following: 
1. Congenital Hyperinsulinemic 
Hypoglycemia (CHH) [19] 
This is a standard name of the condition 
not able to change. This is a classic 
presentation of loss of function mutation of 
KATP channel where there is continued 
depolarization of cell membrane leading to 
persistent Insulin release and severe 
hypoglycemia. This could be a result of the 
KATP channel not reaching the cell 
membrane, or the channel is unresponsive 
to MgADP. Babies are typically born with 
large birth weight and may develop severe 
hypoglycemia and a neurological sequel if 
undiagnosed. CHH is further subdivided 
into focal, diffuse, and atypical variety 
depending on the histological features. 
Commonest is diffuse variety, where all the 
β cells of the pancreas are affected. This is 
often a result of compound heterozygous 
or homozygous recessive mutation [10]. 
Focal variety presents with localised islet 
cell hyperplasia and is due to  paternally 
inherited heterozygous mutation [10] The 
focal variety is due to lack of balanced 
expression of IGF-2 (Insulin-like growth 
factor-2) and H19, CDKN1C (tumor 
suppressor genes). An atypical type 
constitutes poorly defined histology that 
does not fit into a focal or diffuse variety. 
This type is not clearly understood, and no 
clear, mutations have been identified so 
far. 
2.  Neonatal Diabetes 
Patients can present with transient or 
permanent neonatal diabetes [1].     
Activating heterozygous mutations of both 
ABCC8 and KCNJ11 genes have been 
detected in these patients. A study 
conducted on 97 patients who were 
diagnosed with diabetes before six months 
of age documented that the transient 
neonatal diabetes resulting from KATP 
channel mutations always occurs before six 
months of age, remits in early childhood 
and 50% of cases relapse in adolescence or 
early adult life. 
About 71% of these patients had 
chromosome 6q24 abnormality- the 
commonest genetic cause of neonatal 
diabetes and 26% had KATP channel 
abnormalities [7]. This study also showed 
that those cases who did not have 
remission after six months would go on to 
have permanent neonatal diabetes. This is 
as a result of gain of function mutation [7]. 
T2 Diabetes that presents in the first six 
months of life is most likely due to a 
genetic mutation (because Type 1 diabetes 
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does not present this early. Patients born 
KATP channel mutations generally have 
low birth weight) and are easily treated 
with oral sulfonylurea. 
3.  Diabetes in adolescence or early 
adult life: (Unable to change the 
name, this is a standard name) 
It is rare to find ABCC8/KCNJ11 mutations 
in patients presenting with diabetes for the 
first time in early adult life without a 
history of neonatal hypo or hyperglycemia 
[5]. The majority of these patients are 
dominant mutation carriers presenting 
with any of the presentations, glucose 
intolerance, or gestational diabetes or 
diabetes in early adult life or no diabetes at 
all and might simply pass the gene to 
offspring who may present with variable 
penetrance of diabetes. This implies that 
there are undiscovered pathways involved 
in β- cell insulin release besides the KATP 
channel. 
4.  Neurological Manifestations 
It is well known that KATP channels are 
expressed in neural tissue. Nearly 30% of 
the patients [2] presenting with permanent 
neonatal diabetes was noted to have 
concomitant neurological features. The 
neurological symptoms range from autistic 
spectrum disorders, neuropsychological 
abnormalities, sleep disorders, DEND 
syndrome (Developmental delay, epilepsy, 
neonatal diabetes), or as intermediate 
DEND (IDEND) syndrome where epilepsy 
is either not present or appears after 12 
months of life [11, 12, 13]. 
When to suspect Monogenic Diabetes? 
Features suggestive of clinical 
diagnosis of MODY: Onset of diabetes in 
adolescence or young adulthood typically 
before the age of 35 years. 
Features not typical of type 1 diabetes. 
These include: 
No detection of pancreatic islet 
autoantibodies 
Evidence of endogenous insulin production 
beyond honeymoom period ( 3-5 years after 
the onset of diabetes) 
In presence of hyperglycemia measurable 
C-peptide (C-peptide ≥0.60 ng/mL or  
0.2nmol/L)  
Requirement of insulin 0.5U/kg/d (low) 
Omission of insulin does not cause 
ketoacidosis 
Features not typical of type 2 diabetes 
mellitus. These include: 
Age of onset of diabetes before 45 years 
No features of insulin resistance 
Not obese 
No acanthosisnigricans 
No evidence of fatty liver 
Normal or elevated high-density 
lipoprotein cholesterol (HDL-C) and 
normal triglyceride levels  
  Non progressive mild, stable fasting 
hyperglycemia that responds to 
pharmacologic therapy 
Highly sensitive to sulfonylureas 
Extrapancreatic manifestations (e.g [1] 
renal, hepatic, gastrointestinal) 
Personal history or family history of 
neonatal diabetes or neonatal 
hypoglycaemia. 
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There should be a high index of suspicion 
about monogenic diabetes in a child with 
an affected parent with diabetes, and 
particularly if there is ≥ 3 consecutively 
affected generations [5]. 
60-90% of MODY will have an affected 
parent compared to 10% of those with 
Type1 Diabetes [5]. However, a history of 
parent with diabetes alone cannot 
differentiate between Type 2 diabetes 
(T2D) and MODY. In young onset type 2 
cases 50% will have a parent with diabetes.  
Suspicion should increase if the patient is 
not obese or has no metabolic features. 
Biomarkers that can help in the selection of 
individuals for monogenic diabetes genetic 
testing include C- peptides, pancreatic 
auto-antibodies, lipid profiles, and high-
sensitivity C-reactive protein (CRP) which 
has a discriminatory variable value with 
several limitations. 
A combination of clinical and biomarker 
approaches is likely to yield the highest 
sensitivity [5]. Absence of pancreatic 
autoantibodies in a non-obese patient with 
no metabolic features and a detectable C-
peptide 3–5 years after diagnosis increases 
the clinical suspicion. 
In the US SEARCH study, youth diagnosed 
under the age of 30 with diabetes was 
selected for the genetic testing if pancreatic 
autoantibody test was negative and fasting 
C-peptide was 0.8ng/ml. This method 
yielded a detection rate of 8% in the tests 
[5, 15]. 
Availability of an online clinical prediction 
tool for MODY has facilitated the 
calculation of an individual’s probability of 
having MODY. This also provides a rational 
approach to genetic test. The disadvantage 
is that this tool kit only applies to 
individuals younger than age 35 years and 
has been mostly studied in white European 
populations. The prevalence of MODY in 
racial and ethnic minorities may be 
underrepresented as many individuals with 
MODY remain undiagnosed [16]. 
Management 
1.  Congenital Hyperinsulinemic 
Hypoglycemia:  
Diazoxide therapy is useful in patients with 
congenital hypoglycaemia [21]. Diazoxide 
acts through SUR1receptor, causing 
activation of the KATP channel that results 
in opening of the KATP channel, 
hyperpolarisation and a decreased Calcium 
ion influx, thus counteracting Insulin 
release. In patients who show poor 
response to Diazoxide, Somatostatin 
analogs have been tried as the second line 
with beneficial effects. Poor response to 
medical therapy depends on the type of 
defect in the KATP channel (when the 
KATP channel does not traffic to the cell 
membrane from endoplasmic reticulum) 
and severity of the mutation. 
18F-DOPA-PET (fluorine-18 dihydroxy-
phenylalanine positron emission 
tomography) scan can distinguish between 
focal and diffuse types of CHH. Surgical 
resection of focal abnormality can result in 
the resolution of symptoms. However, 
these patients may still develop diabetes 
later in life due to reduced expression of 
proinsulin secretion by the remaining 
pancreatic cells. The diffuse type does not 
respond well to medical therapy and may 
need total pancreatectomy that results in 
diabetes and exocrine pancreatic 
insufficiency. 
2.  Diabetes 
Sulfonylureas are the drug of choice in 
both transient/permanent neonatal 
diabetes and also for diabetes that develops 
later in life. This drug is well tolerated, and 
not many serious adverse effects in terms 
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of hypoglycemia have been reported so far 
[8]. Sulfonylurea binds to the SUR1 
receptor of the KATP channel and closes 
the channel independently of ATP, 
resulting in insulin release. The cause for 
the unresponsiveness to sulfonylurea 
therapy is due to the duration of diabetes, 
severity of the mutations, and duration of 
Insulin therapy prior to the transfer of 
therapy from insulin to sulfonylurea 
following a revision of the diagnosis. In 
patients who have concomitant 
neurological features, larger doses of 
sulfonylurea are recommended, and 
treatment initiation should be as early as 
possible because there is some evidence 
that this may improve the neurological 
features. 
Permanent neonatal diabetes (PND) 
caused by mutations in KCNJ11 or ABCC8 
can be managed with high- dose 
sulfonylurea therapy in 90% of cases. For 
neonatal diabetes, a recent case series of a 
10-year follow- up of individuals with 
KCNJ11 or ABCC8 variants treated with SU 
agents reported that 93% of cases remained 
on SU therapy alone, achieving glycemic 
targets and with a good safety profile. 
3.  Pregnancy 
Management of patients with monogenic 
diabetes and Pregnancy is challenging. 
Factors that need to be considered in these 
patients are:  Maternal Diabetes control, 
mutation status of the fetus,  
Effectosulfonylurea and its transplacental 
transfer of sulfonylurea [10]. Treatment in a 
non-pregnant state is mostly with 
sulfonylureas, but, during pregnancy, the 
benefit of sulfonylurea treatment will 
depend on the fetal genotype. 
Fetal Genotype determines the fetal birth 
weight in the pregnancy affected by the 
KATP channel mutation. Those who 
inherit the mutation from either their 
father or mother can have low birth weight 
due to reduced fetal insulin secretion; 
Sulfonylurea treatment will restore the 
fetal insulin secretion in such cases and can 
result in normal birth weight. On the other 
hand sufonylurea treatment can cause 
excess fetal insulin secretion, macrosomia 
and neonatal hypoglycaemia if the fetus 
has not inherited the mutation. 
The risk from deteriorating glycemic 
control in the mother on a high dose of 
sulfonylurea and its effect on the fetal 
development has to be accounted for. This 
can again result in macrosomia and 
neonatal hypoglycemia in an unaffected 
offspring, who is being exposed to high 
dose sulfonylurea treatment. Chorionic 
villus sampling or amniocentesis can be 
used for fetal genotyping.  These ivasive 
procedures can cause miscarriage [10]. 
Noninvasive cell-free DNA is an option for 
prenatal genetic testing. This could help 
management strategies for many forms of 
monogenic diabetes [10]. 
 As per current recommendations fetal 
genotype can be inferred from serial 
ultrasound growth monitoring starting at 
28 weeks [10]. Reduced growth indicates 
the fetus has inherited the KATP 
channelmutation, while normal growth 
suggests no mutation. 
[10] General treatment guidelines advise to 
switch to insulin prior to conception or to 
continue sulfonylurea treatment through 
the first trimester at the lowest dose to 
maintain good glycemic control with 
HBA1c 6.5. 
 If ultrasound scans show reduced fetal 
growth, indicating that the fetus has 
inherited the KATP channel mutation, 
sulfonylurea (glyburide) is the treatment of 
choice and should be continued or 
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reintroduced if the patient was switched to 
insulin previously. 
If ultrasound scans show normal fetal 
growth then transfer from sulfonylurea to 
insulin in order to avoid excessive fetal 
growth, macrosomia, and neonatal 
hypoglycemia. 
Fetal genetic testing should be done after 
delivery if it was not done during 
pregnancy [10]. If the offspring has 
inherited the KATP channel mutation, 
neonatal diabetes will present before 6 
months of age. A regular follow up with a 
pediatrician is recommended [10]. Maternal 
sulfonylurea treatment can be restarted 
after delivery and is considered to be safe 
during breast feeding, though at high 
maternal doses, may be excreted in the 
breast milk [17, 18, 19]. 
 
Conclusion 
The importance of history taking and 
arriving at a diagnosis of monogenic 
diabetes cannot be stressed enough as it 
carries huge therapeutic implications. The 
case described is a classic example of 
delayed diagnosis of monogenic diabetes 
and inappropriate use of Insulin therapy 
resulting in dangerous hypoglycemia. The 
chances of the patient's son being treated 
as Type 1 diabetes with Insulin therapy 
were high without clinical suspicion of 
monogenic diabetes.  
This would have resulted in the 
challenging management of a 15-year-old 
patient with cerebral palsy. The 
implications of a diagnosis of diabetes in 
childhood and adolescence are profound. 
Cascade testing the family members with 
diabetes and a successful transfer from 
Insulin therapy to sulfonylurea will 
improve glycemic control effectively, but 
also results in a significant decrease in 
disease burden. 
Several members of the patient's family 
have developed diabetes in their twenties, 
with the youngest being the patient's son. 
Although the patient and the son share the 
same novel pathogenic variant, the 
phenotype and presentation of the patient 
are very different from the son who has 
severe neurological features and a biphasic 
presentation of diabetes.  
This variable penetrance of diabetes can 
imply that the KATP channel may not be 
the only responsible pathway involved in 
Insulin release. Further research studies are 
required to explore the molecular 
mechanisms responsible for β-cell Insulin 
release other than KATP channel pathways. 
Even within the KATP channel, it is not 
clear how the four Kir 6.2 subunits are 
orchestrated, as the binding of even one 
subunit with ATP is enough to result in the 
closure of the channel. 
The current challenges in monogenic 
diabetes are lack of awareness and 
understanding of monogenic diabetes 
among medical practitioners, access to 
high quality and cost-effective genetic 
testing, and lack of ethnic studies, as the 
majority of data available are based on the 
population of the European descent [8]. 
Research is needed across all the ethnic 
groups with contributions from national 
and international data. 
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